Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF"

Circulation. 2023 Mar 14;147(11):922-923. doi: 10.1161/CIRCULATIONAHA.122.063395. Epub 2023 Mar 13.

Authors

Senthil Selvaraj^{1

2}, Mikhail N Kosiborod^{3

4}, Svati H Shah^{1

2}

Affiliations

¹ Duke Molecular Physiology Institute, Durham, NC (S.S., S.H.S.).
² Division of Cardiology, Duke University Medical Center, Durham, NC (S.S., S.H.S.).
³ Saint Luke's Mid America Heart Institute, Kansas City, MO (M.N.K.).
⁴ University of Missouri-Kansas City, MO (M.N.K.).

PMID: 36913500
DOI: 10.1161/CIRCULATIONAHA.122.063395

No abstract available

Publication types

Letter

MeSH terms

Benzhydryl Compounds* / pharmacology
Benzhydryl Compounds* / therapeutic use
Glucosides / therapeutic use
Heart Failure* / diagnosis
Heart Failure* / drug therapy
Humans

Substances

dapagliflozin
Benzhydryl Compounds
Glucosides